Top 10 International Stocks For 2014

FactSet has an update on the second-quarter earnings season today, now that 79% of companies have reported.

Of the 393 companies to report so far, 73% have delivered earnings per share ahead of analysts��consensus estimates. Fifty-five percent have reported revenue above expectations. The number of companies with earnings surprises is in-line with the four-year average, however those with revenue beats is below average; nonetheless, the percentage of companies reporting upbeat revenue crossed the 50% mark for only the second time in the past five years.

Looking at individual sectors, Materials (83%), Health Care (82%), and Information Technology (81%) sectors are those with the largest number of companies with better-than-expected earnings, while Services (50%) and Utilities (57%) trailed the pack.

Yet Financials are reporting the largest upside aggregate differences between actual earnings and estimated earnings: Notable beats came from Goldman Sachs (GS), American International Group (AIG), Bank of America (BAC), and JPMorgan (JPM).

Top Sliver Companies For 2015: Pan American Silver Corp.(PAAS)

Pan American Silver Corp. engages in the exploration, development, extraction, processing, production, refining, reclamation, and operation of silver properties. The company also produces and sells gold, zinc, lead, and copper. As of April 27, 2011, it had seven silver mining operations in Mexico, Peru, Argentina, and Bolivia. The company was founded in 1979 and is headquartered in Vancouver, Canada.

Advisors' Opinion:

• [By Tim Melvin]

  Right now I know that silver miners like Pan American Silver (PAAS) and Coeur Mining (CDE) are very cheap on an asset basis. I know that oil and gas producers like Swift Energy (SFY) and WPX Energy (WPX) are priced as if no one will ever use the stuff again. I know that small banks like Cape Bancorp (CBNJ) and Essa Bancorp (ESSA) are crazy-cheap — and if the world does not end, those stocks will be a lot higher in a few years.

• [By Tim Melvin]

  Once again, rather than making a wish on burning match bets, I prefer to buy out of favor companies at a steep discount to their asset and business value. And a�look at the silver miners shows deep discounts to the value of corporate assets that could lead to significant profits.

  Pan American Silver (PAAS) trades at just 65% of book value and has fallen by about 75% over the past few years. Couer Mines (CDE) is fetching just 54% of book and has fallen by around 80% since 2006. Silver Standard Resources (SSRI) trades at 55% of book and for less than the value of the cash the company has in the bank.

  In reality, silver just needs to stop falling in price for these stocks to start to recover. If the analysts are right and silver hits a new high in the next decade, these could easily be the best investments you ever make in your lifetime.

• [By MONEYMORNING]

  A great example was when Minefinders was taken over by Pan American Silver Corp. (Nasdaq: PAAS) in 2012. We earned 56.54% on the sale of a first tranche (before the takeover offer), then 42.12% on the balance of the position once PAAS announced the takeover.

• [By Doug Ehrman]

  The recent sell-off in precious metals has boosted the dividend yield on various silver companies, including Silver Wheaton (NYSE: SLW  ) . Current conditions give investors the chance to own this best-in-class silver streaming company with both a strong income element and plenty of upside. Unlike miners Pan American Silver (NASDAQ: PAAS  ) and Silvercorp Metals (NYSE: SVM  ) , which offer higher dividend yields, Silver Wheaton has important advantages.

Top 10 International Stocks For 2014: Independent Film Development Corp (IFLM)

Independent Film Development Corporation (IFDC), incorporated on September 14, 2007, is in the development stage. The Company focuses on acquiring and developing independent films for production, sales and distribution, with a goal towards partnerships with mini-major and the major film studios, such as Lionsgate and Sony. IFDC�� focus of operations has three main components of film production and finance; Co-financing, acquiring product in the development stage, and its own film production. Co-financing is where a company such as IFDC goes out looking for films that are already financed at 50% or more. The Company licenses partially or fully completed films made by independent filmmakers to entertainment distributions companies.

The Company produces film on behalf of a studio. The Company identifies, produces, and secures distribution of a film. The Company owns the film in perpetuity and directly participates in all revenue generated by the film. The Company identifies films through its network of independent filmmakers as well as industry festivals and trade shows including Sundance, Tribeca, Cannes, and Toronto. The company will acquire the rights to license (as sales agent) films for a period of 7-25 years in return for a commission ranging from 10-30% of the licensing fees paid by the distributors.

Advisors' Opinion:

• [By John Udovich]

  As the year draws to a close, theme park stocks like SeaWorld Entertainment Inc (NYSE: SEAS), Six Flags Entertainment Corp (NYSE: SIX), Cedar Fair, L.P. (NYSE: FUN) and Independent Film Development Corporation (OTCMKTS: IFLM) still have some news for investors to digest for the year closes. Just consider the following news:

Top 10 International Stocks For 2014: AstraZeneca PLC (AZN)

AstraZeneca PLC (AstraZeneca), incorporated on June 17, 1992, is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and Inflammation. It has a range of medicines that includes treatments for illnesses, such as its antibiotic, Merrem/Meronem and Losec/Prilosec for acid related diseases. AstraZeneca�� products include Crestor, Atacand,Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The Company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia. On August 31, 2011, the Company completed the sale of the Astra Tech business to DENTSPLY International Inc. On June 19, 2012, the Company acquired Ardea Biosciences Inc (Ardea), a biotechnology company in San Diego, California. In July 2012, the Company acquired a portfolio of neuroscience assets from Link Medicine Corporation. In August 2012, Alliance Pharma plc�� wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands Paludrine, Avloclor and Savarine from AstraZeneca UK Limited. In August 2012, the Company and Bristol-Myers Squibb Company announced the acquisition of Amylin Pharmaceuticals, Inc. by Bristol-Myers Squibb Company. In June 2013, the Company acquired Pearl Therapeutics.

Cardiovascular

The Company�� marketed products include Crestor (rosuvastatin calcium), Atacand2 (candesartan cilexetil), Seloken/Toprol-XL (metoprolol succinate), Tenormin (atenolol), Plendil (felodipine), Zestril3 (lisinopril dihydrate), Brilinta/Brilique (ticagrelor), and Axanum, (acetylsalicylic acid (ASA). Crestor1 is a statin used for the treatment of dyslipidaemia and hypercholesterolemia. In some markets, it is also indicated to slow the progression of atherosclerosis and to re! duce the risk of first cardiovascular (CV) events. Atacand2 is an angiotensin II antagonist used for the 1st line treatment of hypertension and symptomatic heart failure. Seloken/Toprol-XL is a beta-blocker once-daily tablet used for 24-hour control of hypertension and for use in heart failure and angina.

Tenormin is a cardioselective beta-blocker used for hypertension, angina pectoris and other CV disorders. Plendil is a calcium antagonist used for the treatment of hypertension and angina. Zestril3 is an angiotensin-converting enzyme inhibitor used for the treatment of a wide range of CV diseases, including hypertension. Brilinta/Brilique is an oral antiplatelet for the treatment of acute coronary syndromes (ACS). Axanum is a fixed dose combination indicated for prevention of CV events in high-risk CV patients in need of daily low-dose ASA treatment and who are at risk of gastric ulcers.

The Company�� marketed products for diabetes include Komboglyze ((saxagliptin and metformin HCl), Kombiglyze XR (saxagliptin and metformin XR) and Onglyza (saxagliptin). Komboglyze is an immediate release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with Type 2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets. Kombiglyze XR is an extended release fixed dose combination indicated as an adjunct to diet and exercise to improve glycaemic control in adults with Type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate. Onglyza is a DPP-IV inhibitor used for the treatment of Type 2 diabetes.

Gastrointestinal

AstraZeneca�� marketed products include Nexium (esomeprazole), Losec/Prilosec (omeprazole) and Entocort (budesonide). Nexium is a proton pump inhibitor (PPI) used for the treatment of acid-related diseases to offer clini! cal impro! vements over other PPIs and other treatments. Losec/Prilosec is used for the short-term and long-term treatment of acid-related diseases. Entocort is a corticosteroid used for the treatment of inflammatory bowel disease. Nexium is marketed in approximately 120 countries and is available in oral (tablet/capsules and oral suspension) and intravenous (i.v.) dosage forms for the treatment of acid-related diseases.

Infection

The Company�� marketed products include Merrem/Meronem (meropenem), Cubicin (daptomycin) and FluMist/Fluenz (influenza vaccine live, intranasal). Merrem/Meronem is a carbapenem anti-bacterial used for the treatment of serious infections in hospitalised patients. Cubicin is a cyclic lipopeptide anti-bacterial used for the treatment of serious infections in hospitalised patients. FluMist/Fluenz is an intranasal live, attenuated, trivalent influenza vaccine.

Neuroscience

AstraZeneca�� marketed products include Seroquel IR (quetiapine fumarate), Seroquel XR (an extended release formulation of quetiapine fumarate), Zomig (zolmitriptan), Diprivan (propofol), Vimovo (naproxen/esomeprazole magnesium), Naropin (ropivacaine), Xylocaine (lidocaine) and EMLA (lidocaine and prilocaine). Seroquel IR is an atypical anti-psychotic drug used for the treatment of schizophrenia and bipolar disorder (mania, depression and maintenance). Seroquel XR is used for the treatment of schizophrenia, bipolar disorder, MDD and in some territories for generalised anxiety disorder (GAD).

Zomig is used for the treatment of migraines with or without aura and Zomig Nasal Spray is indicated for the acute treatment of cluster. Diprivan is an intravenous general anaesthetic used in the induction and maintenance of general anaesthesia, for use in intensive care sedation and conscious sedation for surgical as well as diagnostic procedures. Vimovo is a fixed-dose combination of enteric-coated naproxen (an NSAID) with the gastroprotection of immediate release ! esomepraz! ole (a proton pump inhibitor) for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the developing of gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. Naropin is used as a long-acting local anaesthetic, for surgical anaesthesia and acute pain management. Xylocaine is a used short-acting local anaesthetic. EMLA is used as a local anaesthetic for topical application.

Oncology

AstraZeneca�� marketed products include Arimidex (anastrozole), Zoladex (goserelin acetate implant), Casodex (bicalutamide), Iressa (gefitinib), Faslodex (fulvestrant), Nolvadex (tamoxifen citrate) and Caprelsa (vandetanib). Arimidex is an aromatase inhibitor used for the treatment of early breast cancer. Zoladex, in one- and three-month depots, is a luteinising hormone-releasing hormone agonist used for the treatment of prostate cancer, breast cancer and certain benign gynaecological disorders. Casodex is an anti-androgen therapy used for the treatment of prostate cancer.

Advisors' Opinion:

• [By Keith Speights]

  Many are skeptical about Amarin's ability to successfully commercialize Vascepa to its full potential against larger competitors with fish-oil pills. GlaxoSmithKline (NYSE: GSK  ) markets Lovaza and has made nearly $3.8 billion from the drug over the last five years. AstraZeneca (NYSE: AZN  ) bought Omthera Pharmaceuticals in May, primarily to gain its fish-oil drug Epanova.

• [By TaniaC] biopharmaceutical company. AstraZeneca�� products include Crestor, Atacand, Seloken/Toprol-XL, Plendil, Onglyza, Zestril, Symbicort and Zoladex. The company owns and operates a range of research and development (R&D), production and marketing facilities worldwide. AstraZeneca operates in over 100 countries, including China, Mexico, Brazil and Russia.

  Focus on the Diabetes Segment

  For AstraZeneca, its diabetes business grew 60% in the third quarter of fiscal 2013 and contributed to overall growth of 8%. The diabetes franchise made $206 million. U.S. health regulators approved an AstraZeneca drug from a new class of medicines to treat type 2 diabetes after previously rejecting it over safety concerns. The medicine was co-developed by Bristol-Myers Squibb Co. (BMY) and AstraZeneca. AstraZeneca late last year bought out Bristol's stake in its diabetes joint venture for more than $4 billion, including up-front and sales-related milestone payments.

  Farxiga, which has already been available in Europe, belongs to a class of diabetes drugs called SGLT-2 inhibitors that work by blocking reabsorption of glucose by the kidney and increasing its excretion through urine to lower levels of blood sugar.

  It will compete with a similar drug from Johnson & Johnson (JNJ) called Invokana, as well as diabetes medicines from other classes.

  Details of the Drug

  "Farxiga provides an additional treatment option for millions of Americans with type 2 diabetes," Curtis Rosebraugh, of the FDA's Center for Drug Evaluation and Research, said in a statement. The FDA had initially rejected the Astra and Bristol-Myers drug in early 2012 over concerns about possible cancer and heart risks. The companies provided additional data that addressed those concerns to the satisfaction of the advisory panel and the agency.

  Still, as a condition of approval, the FDA is requiring six post-marketing studies, including a cardiovascular outcomes trial to mak

Top 10 International Stocks For 2014: Under Armour Inc.(UA)

Under Armour, Inc. develops, markets, and distributes performance apparel, footwear, and accessories for men, women, and youth primarily in the United States, Canada, and internationally. It offers products made from moisture-wicking synthetic fabrics designed to regulate body temperature and enhance performance regardless of weather conditions. The company provides its products in three fit types: compression (tight fitting), fitted (athletic cut), and loose (relaxed) extending across the sporting goods, outdoor, and active lifestyle markets. Its footwear offerings comprise football, baseball, lacrosse, softball, and soccer cleats; slides; performance training footwear; and running footwear. The company also provides baseball batting, football, golf, and running gloves, as well as licenses bags, socks, headwear, custom-molded mouth guards, and eyewear that are designed to be used and worn before, during, and after competition. Under Armour sells its products through retai l stores, as well as directly to consumers through its own retail outlets and specialty stores, Website, and catalogs. The company was founded in 1996 and is headquartered in Baltimore, Maryland.

Advisors' Opinion:

• [By Andrew Marder]

  One way that apparel companies are pushing the boundaries is by expanding their consumer base. Companies that had focused on men's clothing are offering women's lines, and vice versa. Two brands that are seeing some great success already are Under Armour (NYSE: UA  ) and Coach (NYSE: COH  ) . The gender expansion plays a big role in these companies' futures, and their actions are laying out a path for others to follow.

• [By Robert Eberhard]

  I like to think that I've shifted my mentality a bit over the past 18 months. I feel more like an investor than ever before, and plan on holding onto many of my investments for a long time. Once I make an investment decision, I try to avoid thinking about other opportunities that I let slip away. Alas, I am human, and my choice of Under Armour (NYSE: UA  ) last year over a group of other qualified candidates has had me thinking recently about the way I make investment decisions. Instead of dwelling on the missed gains, however, I decided to learn from the decision and adjust my thinking going forward.

• [By Ben Levisohn]

  Under Armour�(UA) has gained 0.2% to $78.65 in pre-open trading after being downgraded to Neutral from Positive at Susquehanna.

  Potash Corp.�(POT) has gained 1.9% to $33.10 on speculation that a spat between Belarus and Uralkali may be close to getting resolved.

• [By Ben Levisohn]

  Sbhares of Lululemon have slipped 2.3% to $40.53, while Nike (NKE) has fallen 0.9% to $78.78, Under Armour (UA) has dropped 0.9% to $69.45 and Gap (GPS), whose Athleta brand competes with Lululemon, is off 0.3% at $46.06.

Top 10 International Stocks For 2014: Spdr S&P Homebuilders Etf (XHB)

SPDR S&P Homebuilders ETF (the Fund) seeks to replicate as closely as possible, before expenses, the performance of the S&P Homebuilders Select Industry Index (the Index). To accomplish this, the Fund utilizes a passive or indexing approach and attempts to approximate the investment performance of its Index, by investing in a portfolio of stocks intended to replicate the Index.

The S&P Homebuilders Select Industry Index seeks to provide a representation of the homebuilders��sub-industry portion of the S&P Total Market Index. The S&P TMI tracks all the United States common stocks regularly traded on the NYSE, American Stock Exchange, NASDAQ National Market and NASDAQ Small Cap Exchanges. The Homebuilders Index is an equal weighted market cap index.

Advisors' Opinion:

• [By Anora Mahmudova]

  The day�� economic data provided a little support. The sales pace of existing homes ticked down in March to the slowest rate since July 2012, according to data released Tuesday, however the decline was smaller than the consensus rate forecast by economists polled by MarketWatch. The SPDR S&P Homebuilder ETF (XHB) �gained 1%.

• [By John Maxfield]

  Meanwhile, housing is feeling the effects via higher mortgage rates. For portions of last year, a 30-year conventional mortgage carried an interest rate of less than 3.5%. Since the Fed's announcements, the same rate has climbed back to more than 4%. This is sending shivers through homebuilders' stocks, as the net effect is to make homes more expensive. The SPDR S&P Homebuilders (NYSEMKT: XHB  ) ETF, which tracks the housing sector, is down almost 9% since May 22.

• [By Ben Levisohn]

  The SPDR S&P Homebuilders ETF (XHB) has dropped 10.5% during the past three months, or about when all the talk about an end to the Fed’s bond buying really picked up, compared to a 2.7% return for the S&P 500.

• [By Jon C. Ogg]

  1. The U.S. economy grows 3% as housing starts surpass one million and private employment hits an all-time high – All time high on private employment? 1 million housing starts?

  Homebuilder ETF: SPDR S&P Homebuilders ETF (NYSEArca: XHB) as it is tied to homebuilders and building products rather than including other sectors that only overlap in building. At $32.57, its 52-week range is 426.94 to $33.38. Housing Starts were always well over 1 million on an annualized basis each month before the recession, but they only reached that in two months of 2013 (St. Louis Fed data).

  2. 10-Year Treasury yields move toward 3.5% as the Federal Reserve completes tapering and holds short-term rate near zero – This may sound bad, but it is actually good and fits in line with rates not rising too much. Keep in mind that the 10-year Treasury is at 2.94% now and ended at 3.03% on the last day of 2013. Elsewhere on the yield curve, Doll sees many parts of the fixed income market to end 2014 with negative total rates of return.

Top 10 International Stocks For 2014: AAON Inc.(AAON)

AAON, Inc., together with its subsidiaries, engages in the manufacture and sale of air conditioning and heating equipment primarily in the United States and Canada. The company offers rooftop units, chillers, air-handling units, make-up air units, heat recovery units, condensing units, commercial self contained units, and coils. It serves the commercial and industrial new construction and replacement markets. AAON, Inc. sells its products through manufacturers representatives and internal sales force. The company was founded in 1987 and is based in Tulsa, Oklahoma.

Advisors' Opinion:

• [By Jonas Elmerraji]

  We're seeing the exact same setup in shares of small-cap HVAC firm Aaon (AAON). The biggest difference is that in AAON's case, the ascending triangle pattern is coming in at the top of this stock's recent price action, not at the bottom. That makes this a more textbook trade for September.

  Another important difference is the fact that AAON hasn't triggered yet. Shares have been coiling below $26 resistance since the middle of the summer; a breakout above that $26 level is the indicator that it's time to buy. Whenever you're looking at any technical price pattern, it's critical to think in terms of buyers and sellers. Triangles and other price pattern names are a good quick way to explain what's going on in this stock, but they're not the reason it's tradable. Instead, it all comes down to supply and demand for shares.

  That resistance line at $26 is a price where there's an excess of supply of shares; in other words, it's a place where sellers have been more eager to take recent gains and sell their shares than buyers have been to buy. That's what makes the move above it so significant -- a breakout indicates that buyers are finally strong enough to absorb all of the excess supply above that price level.

  Wait for that to happen before you put your money on this trade.

Top 10 International Stocks For 2014: Janus Capital Group Inc (SLS)

Janus Capital Group Inc., and its subsidiaries (JCG), incorporated on January 23, 1998, provide investment management, administration, distribution and related services to financial advisors, individuals and institutional clients through mutual funds, other pooled investment vehicles, separate accounts and sub advised relationships (collectively referred to as investment products) in both domestic and international markets. JCG provides investment management competencies across a range of disciplines, including fundamental the United States and global equities (growth and value), mathematical equities, fixed income and alternatives through its subsidiaries, Janus Capital Management LLC (Janus), INTECH Investment Management LLC (INTECH) and Perkins Investment Management LLC (Perkins). JCG's investment products are distributed through three primary channels: retail intermediary, institutional and international.

The institutional channel serves the United States corporations, endowments, foundations, Taft-Hartley funds and public fund clients and focuses on distribution direct to the plan sponsor and through consultants. As of December 31, 2012, assets in the institutional channel totaled 24% of total Company assets under management. The international channel primarily serves professional retail and institutional investors outside of the United States, including central and local government pension plans, corporate pension plans, multi-managers, insurance companies and private banks. International products are offered through separate accounts, sub advisory relationships and Janus Capital Funds Plc, a mutual fund trust. As of December 31, 2012, assets in the international channel totaled 11% of total Company assets under management. JCG operates international offices in London, Paris, Milan, Munich, Frankfurt, The Hague, Dubai, Zurich, Singapore, Hong Kong, Tokyo, Melbourne and Taipei. The retail intermediary channel serves financial advisors, third-party intermediaries and retirement platf! orms in the United States. In addition, this channel serves existing individual investors who invest in JCG products through a mutual fund supermarket or directly with JCG. As of December 31, 2012, assets in the retail intermediary channel totaled 65% of total Company assets under management.

Janus

Janus manages primarily growth equity portfolios. As of December 31, 2012, Janus managed 63% of total Company assets under management. The Janus Overseas Fund is included in the assets managed by Janus and represented approximately 6% during the year ended December 31, 2012.

INTECH

INTECH has managed institutional portfolios. INTECH's investment process is based on a mathematical theorem that seeks to add value for clients by capitalizing on the volatility in stock price movements. As of December 31, 2012, INTECH managed 26% of total Company assets under management.

Perkins

Perkins has managed value-disciplined investment products. With its fundamental research and careful consideration for downside risk, Perkins has established itself as a value manager. Perkins offers value equity investment products across a range of the United States asset classes and global equity. As of December 31, 2012, Perkins managed 11% of total Company assets under management.

Advisors' Opinion:

• [By Victor Selva]

  In addition, leading the solid rocket propellant market should ensure increased annual revenue. The new Space Launch System (SLS), for which ATK is working with the NASA, is expected be as successful as the Space Shuttle program years ago.